Shares of Rhythm Pharmaceuticals rose over 2% in light trading following FDA's acceptance of their drug application for chronic weight management in patients with Bardet-Biedl syndrome. The company also develops treatments for rare diseases. It reported revenue growth and positive institutional buying interest.